Mesenchymal stromal cell-derived membrane particles: A novel cell-free therapy for inflammatory bowel diseases.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam ; New York : Elsevier Science, c2001-
    • Subject Terms:
      Inflammatory Bowel Diseases*/therapy ; Colitis*/therapy ; Colitis*/drug therapy ; Mesenchymal Stem Cells*; Animals ; Mice ; Mice, Inbred C57BL ; Disease Models, Animal ; Dextran Sulfate ; Colon ; Inflammation ; Culture Media, Conditioned/pharmacology ; Cytokines/therapeutic use
    • Abstract:
      Inflammatory bowel diseases (IBD), including ulcerative colitis, are chronic and idiopathic inflammations of the gastrointestinal tract. A disruption of the epithelial barrier and an imbalance between Th1 and Th2 subsets are associated with the onset and progression of these diseases. Mesenchymal stromal cells (MSC) are a promising therapy for IBD. However, cell-tracking studies have shown that intravenously infused MSC localize to the lungs and present short-term survival. To reduce practical complexities arising from living cells, we generated membrane particles (MP) from MSC membranes, which possess some of the immunomodulatory properties of MSC. This study investigated the effect of MSC-derived MP and conditioned media (CM) as cell-free therapies in the dextran sulfate sodium (DSS)-induced colitis model. Acute colitis was induced in C57BL/6 mice by oral administration of 2% DSS in drinking water ad libitum from days 0 to 7. Mice were treated with MP, CM, or living MSC on days 2 and 5. Our findings revealed that MP, CM, and living MSC ameliorated DSS-induced colitis by reducing colonic inflammation, the loss of colonic goblet cells, and intestinal mucosa permeability, preventing apoptosis of damaged colonic cells and balancing Th1 and Th2 activity. Therefore, MSC-derived MP have high therapeutic potential for treating IBD, overcoming the deficiencies of living MSC therapy, and opening novel frontiers in inflammatory diseases medicine.
      Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2023 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Cell-free therapy; Immunomodulation; Inflammatory bowel diseases; Inflammatory diseases; Mesenchymal stromal cells; Mesenchymal stromal cells membrane particles; Ulcerative colitis
    • Accession Number:
      9042-14-2 (Dextran Sulfate)
      0 (Culture Media, Conditioned)
      0 (Cytokines)
    • Publication Date:
      Date Created: 20230408 Date Completed: 20230425 Latest Revision: 20230425
    • Publication Date:
      20230425
    • Accession Number:
      10.1016/j.intimp.2023.110076
    • Accession Number:
      37030123